Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ib/IIa study of intratumoral T3011 herpesvirus injection in advanced melanoma
CTR20233828Phase 2Active
- Sponsor
- ImmVira
- Start
- Jan 2024
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of MVR-T3011 in melanoma, sponsored by ImmVira. Started Jan 2024; status: active.
02
Drugs
MVR-T3011
03
Conditions
melanoma
Beyond the preview
Go deeper on CTR20233828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233828.